Dog Vaccines

Dog Vaccines Market Outlook

The global dog vaccines market is estimated to reach USD 3.12 billion by 2035, growing at a CAGR of 6.5% during the forecast period from 2025 to 2035. The increasing pet ownership across the globe, coupled with rising awareness regarding the importance of vaccinations for dogs, has contributed significantly to the growth of this market. Additionally, the growing prevalence of canine diseases and the rising demand for effective preventive healthcare solutions are driving the need for various types of vaccines. Furthermore, advancements in veterinary medicine and technology, including the development of innovative vaccine formulations, are expected to propel market growth in the coming years. Regulatory support and initiatives aimed at ensuring the safety of pets also play a crucial role in fostering a conducive environment for market expansion.

Growth Factor of the Market

Several factors are contributing to the growth of the dog vaccines market. Firstly, the increasing trend of pet humanization, where dogs are treated as family members, has led pet owners to invest more in their health and well-being, including vaccinations. Secondly, there is a growing awareness among pet owners about the dangers of infectious diseases that can be prevented through vaccination, leading to higher demand for both core and non-core vaccines. Furthermore, the rise in the number of veterinary clinics and hospitals providing specialized vaccination services is enhancing accessibility for pet owners, thus stimulating market growth. The ongoing research and development efforts aimed at creating more effective and safer vaccines are also driving innovations and adoption within the market. Additionally, government initiatives promoting vaccination campaigns to control the spread of diseases among dog populations are fostering a favorable market environment.

Key Highlights of the Market

• The market is projected to reach USD 3.12 billion by 2035.
• North America holds the largest market share due to high pet ownership rates.
• The preventive care application segment dominates the market.
• Attenuated live vaccines are the most widely used product type.
• Online stores are emerging as a significant distribution channel for dog vaccines.

By Product Type

Attenuated Live Vaccines:

Attenuated live vaccines are among the most common types of dog vaccines used today. These vaccines contain live pathogens that have been modified to eliminate their virulence while still provoking a strong immune response. This type of vaccine is particularly effective because it stimulates both humoral and cell-mediated immunity, providing dogs with robust protection against diseases such as canine distemper and parvovirus. The significant advantage of attenuated live vaccines is their ability to create long-lasting immunity with fewer doses. Their popularity is further enhanced by the fact that they often lead to a faster immune response compared to inactivated vaccines, making them a preferred choice for many veterinary professionals.

Conjugate Vaccines:

Conjugate vaccines consist of polysaccharides from the pathogen bound to a protein carrier, which enhances the immune response. Although less common than other types, they are specifically useful in protecting against certain types of bacterial infections that are not effectively addressed by traditional vaccines. The conjugate vaccines allow for an extended immune response and can be administered to dogs at various stages of their lives. Their potential in enhancing vaccine efficacy against diseases such as leptospirosis contributes to their growing significance in the dog vaccines market. The development of these vaccines is crucial, especially in areas where bacterial infections are prevalent and pose a significant risk to canine health.

Inactivated Vaccines:

Inactivated vaccines are made from pathogens that have been killed or inactivated and cannot cause disease, making them a safe option for vaccination. These vaccines are highly reliable and are widely used to protect dogs from serious and contagious diseases such as rabies. Generally, inactivated vaccines are considered safer than live vaccines, especially for dogs with compromised immune systems. However, they may require multiple doses to achieve the desired immunity and often need to be combined with adjuvants to enhance their effectiveness. The market for inactivated vaccines continues to grow as veterinarians increasingly recommend them in routine vaccination schedules for dogs, especially in high-risk populations.

Subunit Vaccines:

Subunit vaccines incorporate only parts of the pathogen, such as proteins or sugars, which can stimulate an immune response without introducing the entire pathogen. This type of vaccine is gaining traction due to its safety profile and ability to provide effective immunity with fewer side effects. Subunit vaccines are particularly advantageous for dogs that are sensitive or have adverse reactions to traditional vaccines. The ongoing research into the development of subunit vaccines is expanding the options available to veterinarians and pet owners. As a result, the adoption of subunit vaccines is expected to grow as more formulations become available for various canine diseases, enhancing overall canine health.

DNA Vaccines:

DNA vaccines represent a novel approach to immunization, utilizing genetically engineered DNA to stimulate an immune response. This innovative type of vaccine is designed to introduce specific genes from pathogens into the host cells, enabling the dog's immune system to recognize and fight the actual pathogen when exposed in the future. While still in the experimental stages for many diseases, DNA vaccines offer several potential advantages, including ease of production, stability during storage, and the possibility of eliciting a strong immune response with a single dose. As research progresses and more data becomes available, DNA vaccines are poised to play an increasingly important role in canine vaccination protocols, particularly for diseases that are challenging to address with existing vaccine types.

By Application

Preventive Care:

The preventive care application segment holds a significant share of the dog vaccines market, as vaccination is a fundamental aspect of canine healthcare. Vaccines aimed at preventing common infectious diseases, such as parvovirus, distemper, and rabies, are crucial for maintaining the health of the canine population. Preventive vaccines are administered during a dog's early life and are often part of a regular vaccination schedule to protect against highly contagious and potentially fatal diseases. The importance of preventive care in veterinary medicine cannot be overstated, as it helps reduce the incidence of disease outbreaks and promotes the overall health and longevity of dogs. The growing awareness of the benefits of preventive healthcare among pet owners is a driving factor for this segment's growth.

Therapeutics:

The therapeutics application segment is emerging as a vital area within the dog vaccines market, focusing on vaccines designed to treat existing diseases rather than simply preventing them. These vaccines are being developed for various health conditions, including cancer and autoimmune diseases, aiming to enhance the therapeutic options available to veterinarians. The increasing prevalence of chronic diseases in dogs, coupled with advancements in veterinary oncology and immunology, is driving research and development in this area. Therapeutic vaccines hold great promise and may significantly alter the landscape of canine healthcare by providing new avenues for treatment, reducing the dependency on traditional pharmaceuticals, and improving the quality of life for affected dogs.

By Distribution Channel

Veterinary Hospitals:

Veterinary hospitals are a primary distribution channel for dog vaccines, primarily due to their role as trusted healthcare providers for pets. These facilities offer comprehensive veterinary services, including vaccinations, diagnostic tests, and medical treatments, making them a convenient choice for pet owners. The presence of skilled veterinarians ensures that dogs receive appropriate vaccinations according to their health status and risk factors. Furthermore, veterinary hospitals often have access to the latest vaccine formulations and protocols, allowing for effective vaccination programs. The growing number of veterinary hospitals and their focus on preventive care are contributing to the expansion of this distribution channel in the dog vaccines market.

Veterinary Clinics:

Veterinary clinics serve as another crucial distribution channel for dog vaccines, providing specialized services related to pet care and vaccination. These clinics often focus on preventive care and routine vaccinations, making them accessible and convenient options for pet owners. Many veterinary clinics have established strong relationships with local pet owners, fostering loyalty and continued patronage for vaccination and other health services. The increasing number of small animal veterinary clinics and the emphasis on preventive health care are driving growth in this segment. With clinics often offering flexible hours and personalized services, they are becoming popular destinations for vaccination needs.

Pharmacies:

Pharmacies are playing an increasingly important role in the distribution of dog vaccines, particularly in areas where veterinary access may be limited. Many pharmacies have started to offer pet owners the ability to purchase vaccines directly, allowing for a more convenient vaccination process. This trend is supported by growing partnerships between veterinarians and pharmacies to ensure that proper guidelines are followed during the vaccination process. The rise in the number of pet owners interested in administering vaccines themselves, along with pharmacy staff trained in veterinary health, is further enhancing this distribution channel's potential. As the demand for accessible healthcare solutions for pets continues to grow, pharmacies are expected to remain integral to the dog vaccines market.

Online Stores:

Online stores have emerged as a significant distribution channel for dog vaccines in recent years, providing pet owners with the convenience of purchasing vaccines from home. The rise of e-commerce has enabled pet owners to access a wider range of vaccines and health products, often at competitive prices. This channel offers the advantage of home delivery, which is especially appealing to owners of multiple pets or those living in rural areas with limited access to veterinary clinics. However, it is imperative for consumers to ensure that they purchase from reputable online sources to avoid counterfeit products. The growing trend of digitalization in retail, paired with increasing familiarity with online shopping among pet owners, is expected to sustain the growth of this segment in the dog vaccines market.

By Ingredient Type

Canine Distemper Virus:

The canine distemper virus (CDV) is a significant pathogen affecting dogs, and vaccines targeting this virus are essential for preventive healthcare. CDV is a highly contagious virus that can cause severe respiratory, gastrointestinal, and neurological issues in infected dogs. Vaccination against CDV is usually part of the core vaccination regimen, as it is critical to protect dogs from this potentially fatal disease. The effective prevention of canine distemper through vaccination has led to a decrease in cases, demonstrating the importance of this ingredient type in the overall dog vaccines market. Continued research and development in CDV vaccines aim to enhance efficacy and safety, ensuring optimal protection for dogs.

Canine Parvovirus:

Canine parvovirus (CPV) is another critical ingredient type in dog vaccines, known for causing severe gastrointestinal illness in dogs, particularly in puppies. Vaccines targeting CPV are crucial due to the virus's high transmissibility and the devastating effects it can have on a dog's health. Vaccination against parvovirus is typically included in the core vaccination schedule, providing essential protection to young puppies as they are particularly vulnerable to severe illness. The widespread use of parvovirus vaccines has effectively reduced the incidence of CPV infections, highlighting their importance in canine healthcare. Continued advancements in vaccine formulations aim to improve the immunogenicity and safety profile of parvovirus vaccines to ensure optimal protection against this disease.

Canine Adenovirus:

Canine adenovirus vaccines protect against infectious canine hepatitis and are considered a core vaccine for dogs. The adenovirus is highly infectious and can lead to severe liver damage, making vaccination crucial for maintaining canine health. The vaccine helps stimulate an immune response that protects dogs from the complications associated with this viral infection. This ingredient type is essential for ensuring that dogs remain free from deadly diseases, particularly in regions where canine adenovirus poses a significant risk. The continuous monitoring of adenovirus strains and the development of effective vaccines are vital to adapting to emerging threats and ensuring the continued well-being of the canine population.

Rabies Virus:

Rabies is a viral disease that poses a severe threat to both canine and human health, making rabies vaccines a legal requirement in many regions. Vaccination against rabies is critical for preventing the spread of this fatal disease, which is transmitted through the bite of an infected animal. The rabies vaccine is typically administered as part of a dog's core vaccination schedule, with booster shots recommended at regular intervals to maintain immunity. The global focus on public health and safety has led to stringent regulations regarding rabies vaccination, contributing to the growth of this ingredient type in the dog vaccines market. Ongoing research aims to improve the safety and efficacy of rabies vaccines and adapt to evolving epidemiological trends.

Leptospira:

Leptospira vaccines protect against leptospirosis, a bacterial infection that can lead to serious health complications in dogs and is zoonotic in nature. These vaccines are particularly important in areas where exposure to contaminated water sources is prevalent, as leptospirosis can be transmitted through environmental reservoirs. The demand for leptospirosis vaccines is growing alongside increased awareness of the disease's risks and complications. Vaccination is essential for preventing outbreaks and ensuring the health and safety of both dogs and their owners. The development of effective leptospirosis vaccines is critical, and ongoing research focuses on improving vaccine formulations and expanding their availability in the market.

By Region

The North American region holds the largest share of the global dog vaccines market, primarily fueled by high pet ownership rates and a robust veterinary healthcare system. The region is characterized by a significant emphasis on preventive healthcare for pets, leading to a well-established vaccination culture among dog owners. The increasing incidence of canine diseases, coupled with advancements in vaccine technology, has heightened the demand for dog vaccinations in this region. Furthermore, the presence of numerous leading veterinary pharmaceutical companies and research institutions in North America is driving innovation and improving access to vaccines. With an expected CAGR of 6.8% during the forecast period, the North American market is poised for sustained growth due to these favorable conditions.

In Europe, the dog vaccines market is witnessing steady growth due to increasing awareness of pet health and welfare, coupled with stringent regulations regarding animal healthcare. The European market is characterized by a strong focus on preventive care, with a significant portion of dog owners adhering to vaccination schedules. The rising prevalence of zoonotic diseases and the push for responsible pet ownership practices are also contributing to market growth. Additionally, collaborations between veterinary professionals and pharmaceutical companies are fostering the development of advanced vaccine formulations, further enhancing the market landscape. The European dog vaccines market is expected to grow at a CAGR of 5.5% during the forecast period, supported by these key drivers.

Opportunities

The dog vaccines market presents numerous opportunities driven by various factors, including increasing pet ownership and rising awareness regarding pet health. As more households adopt dogs as family members, the demand for comprehensive healthcare solutions, including vaccines, is on the rise. Additionally, the shift in consumer behavior towards preventive healthcare and wellness for pets has heightened the importance of vaccination as a key component of overall pet health management. Companies focusing on innovation and the development of novel vaccine formulations, such as DNA and subunit vaccines, are likely to find significant market opportunities as these products gain traction among veterinary professionals and pet owners alike. Furthermore, the ongoing integration of technology in veterinary practices, such as telemedicine and pet health apps, can facilitate improved access to vaccine information and services, further driving growth opportunities in this market.

Moreover, the growing trend of e-commerce and online pet health products provides an innovative channel for vaccine distribution. The ability to purchase vaccines through online platforms allows pet owners greater convenience and access to a wider variety of products. Companies that invest in establishing strong online presences and partnerships with e-commerce platforms can capitalize on this trend to boost sales and market penetration. The rising focus on global health initiatives, including vaccination campaigns and educational programs, can also serve as a catalyst for market growth, as they aim to improve knowledge about the importance of vaccinations in controlling preventable diseases among dogs. These opportunities collectively indicate a promising future for the dog vaccines market, driven by evolving consumer demands and industry innovations.

Threats

One of the significant threats to the dog vaccines market is the rising prevalence of counterfeit vaccines and unregulated products being sold through unofficial channels. As the demand for pet vaccinations increases, some unscrupulous entities may attempt to capitalize on this trend by supplying counterfeit or substandard vaccines, which can pose severe health risks to dogs and undermine the trust of pet owners in legitimate products. This situation presents a challenge for reputable vaccine manufacturers and veterinary professionals who prioritize safe and effective immunization practices. Additionally, the regulatory landscape surrounding vaccines is evolving, and companies must remain compliant with changing regulations, which can lead to increased operational costs and potential disruptions in supply chains.

Another threat to the market is the growing concern over vaccine hesitancy among pet owners, influenced by misinformation and a lack of understanding regarding the benefits of vaccination. Pet owners may delay or forego vaccinations due to misconceptions about vaccine safety and effectiveness, leading to an increased risk of disease outbreaks within the canine population. Tackling this issue requires concerted efforts from veterinary professionals, regulatory bodies, and manufacturers to provide accurate information and education to pet owners regarding the critical nature of vaccinations in promoting pet health. Addressing these challenges is essential for ensuring a sustainable future for the dog vaccines market.

Competitor Outlook

• Zoetis Inc.
• Merck Animal Health
• Boehringer Ingelheim
• Elanco Animal Health
• Virbac Corporation
• Ceva Sante Animale
• Vetoquinol S.A.
• Heska Corporation
• Phibro Animal Health Corporation
• Merial (part of Boehringer Ingelheim)
• Neogen Corporation
• IDEXX Laboratories
• Dechra Pharmaceuticals PLC
• Novartis Animal Health
• Vaxxinova International B.V.

The competitive landscape of the dog vaccines market is characterized by a mix of established players and emerging companies, all vying for market share in this rapidly evolving sector. Major companies such as Zoetis, Merck Animal Health, and Boehringer Ingelheim dominate the market with their extensive portfolios of vaccines and veterinary products. These companies invest heavily in research and development to innovate and enhance the efficacy and safety of their vaccine offerings. Additionally, they engage in strategic partnerships and collaborations with veterinary clinics and hospitals, which serve as vital distribution channels for their products. The competitive environment is further intensified by the presence of specialized companies focused on niche markets, such as the development of innovative vaccine technologies and formulations.

Zoetis Inc. is a leading player in the dog vaccines market, recognized for its comprehensive range of vaccines targeting various canine diseases. The company emphasizes innovation and regularly invests in research to develop next-generation vaccine solutions. Their commitment to enhancing vaccine safety and efficacy is reflected in their extensive portfolio, which includes both core and non-core vaccines. Merck Animal Health, another prominent player, is known for its broad spectrum of veterinary vaccines, including those for rabies and distemper. Merck places a strong emphasis on maintaining high-quality standards and ensuring that its products meet the evolving needs of veterinarians and pet owners.

Boehringer Ingelheim has solidified its position in the market through its diverse range of vaccines tailored to canine health. The company's focus on research and development has led to the introduction of innovative products that address emerging health threats in the canine population. Their commitment to veterinary health is evident in their collaborative efforts with veterinarians to improve education and awareness regarding vaccination practices. Elanco Animal Health and Virbac Corporation are also notable players in the market, both of which are committed to providing high-quality vaccines and products that contribute to the health and well-being of dogs. The competitive landscape in the dog vaccines market is dynamic and continues to evolve with the introduction of innovative technologies, changing consumer preferences, and regulatory developments.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Zoetis Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Vetoquinol S.A.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Heska Corporation
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Ceva Sante Animale
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 IDEXX Laboratories
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Neogen Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Virbac Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck Animal Health
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Boehringer Ingelheim
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Elanco Animal Health
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Novartis Animal Health
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Dechra Pharmaceuticals PLC
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Vaxxinova International B.V.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Phibro Animal Health Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Merial (part of Boehringer Ingelheim)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Dog Vaccines Market, By Application
    • 6.1.1 Preventive Care
    • 6.1.2 Therapeutics
  • 6.2 Dog Vaccines Market, By Product Type
    • 6.2.1 Attenuated Live Vaccines
    • 6.2.2 Conjugate Vaccines
    • 6.2.3 Inactivated Vaccines
    • 6.2.4 Subunit Vaccines
    • 6.2.5 DNA Vaccines
  • 6.3 Dog Vaccines Market, By Ingredient Type
    • 6.3.1 Canine Distemper Virus
    • 6.3.2 Canine Parvovirus
    • 6.3.3 Canine Adenovirus
    • 6.3.4 Rabies Virus
    • 6.3.5 Leptospira
  • 6.4 Dog Vaccines Market, By Distribution Channel
    • 6.4.1 Veterinary Hospitals
    • 6.4.2 Veterinary Clinics
    • 6.4.3 Pharmacies
    • 6.4.4 Online Stores

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Dog Vaccines Market by Region
  • 10.3 Asia Pacific - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 India
      • 10.3.1.2 China
      • 10.3.1.3 Japan
      • 10.3.1.4 South Korea
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Dog Vaccines market is categorized based on

By Product Type

• Attenuated Live Vaccines
• Conjugate Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• DNA Vaccines

By Application

• Preventive Care
• Therapeutics

By Distribution Channel

• Veterinary Hospitals
• Veterinary Clinics
• Pharmacies
• Online Stores

By Ingredient Type

• Canine Distemper Virus
• Canine Parvovirus
• Canine Adenovirus
• Rabies Virus
• Leptospira

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Zoetis Inc.
• Merck Animal Health
• Boehringer Ingelheim
• Elanco Animal Health
• Virbac Corporation
• Ceva Sante Animale
• Vetoquinol S.A.
• Heska Corporation
• Phibro Animal Health Corporation
• Merial (part of Boehringer Ingelheim)
• Neogen Corporation
• IDEXX Laboratories
• Dechra Pharmaceuticals PLC
• Novartis Animal Health
• Vaxxinova International B.V.